Trial List
List all clinical trials by discovery date. Accepts regular expressions in search.
GET /trials/?format=api&page=3
http://api.gregory-ms.com/trials/?format=api&page=4", "previous": "http://api.gregory-ms.com/trials/?format=api&page=2", "results": [ { "trial_id": 4292, "title": "The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs in Patients With Multiple Sclerosis", "summary": null, "published_date": "2024-02-16T00:00:00Z", "discovery_date": "2024-03-13T11:01:28.548595Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06293079", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06293079" }, "categories": [ { "category_id": 18, "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs", "category_name": "Physical therapy and Telerehabilitation", "category_slug": "physical-therapy-and-telerehabilitation", "category_terms": [ "telerehabilitation", "physical therapy", "virtual reality", "gamification", "neurostimulation", "cognitive training", "spasticity", "motor control" ], "article_count": 174 } ], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13797894", "last_refreshed_on": "2024-03-11", "scientific_title": "The Effect of Hybrid Telerehabilitation-Based Structured Exercise Programs on Gait, Functional Capacity, EMG Muscle Activation and Fatigue in Patients With Multiple Sclerosis", "primary_sponsor": "Biruni University", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "65 Years", "inclusion_gender": "All", "date_enrollement": "2023-08-30", "target_size": "45", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Investigator, Outcomes Assessor).", "phase": "N/A", "countries": "Turkey", "contact_firstname": "; ;", "contact_lastname": "Guzin Kaya Aytutuldu;Güzin Kaya Aytutuldu;Güzin Kaya Aytutuldu", "contact_address": null, "contact_email": ";[email protected];[email protected]", "contact_tel": ";05366265884;05366265884", "contact_affiliation": "Biruni University;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - EDSS score of 0 - 4.0\r<br>\r<br> - Having high-speed internet access via smartphone or computer\r<br>\r<br> - Getting at least 24 points from the Mini Mental Test\r<br>\r<br> - Being at Stage 3 or above according to the Functional Ambulation Scale.\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Having hearing or vision problems.\r<br>\r<br> - Participating in any exercise program.\r<br>\r<br> - Having other accompanying neurological, cardiovascular or orthopedic disorders\r<br>\r<br> - A history of MS attacks or a change in medication in the last 6 months.\r<br>\r<br> - Being in a physical condition that cannot do the exercises.\r<br>\r<br> - Comorbid conditions that negatively affect oxygen transport (severe anemia, peripheral\r<br> artery diseases, etc.)\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: Exercise Program", "primary_outcome": "Gait Speed;Functional Capacity", "secondary_outcome": "EMG muscle activation;EMG muscle activation;Modified Fatigue Impact Scale", "secondary_id": "Researcher;BiruniUnive", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4291, "title": "The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis", "summary": null, "published_date": "2024-02-20T00:00:00Z", "discovery_date": "2024-03-13T11:01:28.491638Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06290453", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06290453" }, "categories": [], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13797692", "last_refreshed_on": "2024-03-11", "scientific_title": "The Regulatory Role of miRNA 27 and Follistatin Like Protein-1 Gene in the Pathophysiology of Multiple Sclerosis Patients.", "primary_sponsor": "Assiut University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "20 Years", "inclusion_agemax": "45 Years", "inclusion_gender": "Female", "date_enrollement": "2024-03-27", "target_size": "60", "study_type": "Observational", "study_design": null, "phase": null, "countries": null, "contact_firstname": "", "contact_lastname": "Rasha Mohammed, Lecturer", "contact_address": null, "contact_email": "[email protected]", "contact_tel": "01010024021", "contact_affiliation": null, "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> 1. Patients diagnosed with MS based on the revised McDonald criteria.\r<br>\r<br> 2. Female patients will only be included.\r<br>\r<br> 3. 20- 45 years old.\r<br>\r<br> 4. Drug naïve.\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - 1. Patients with other neurodegenerative and autoimmune disorders. 2. Pregnant\r<br> females. 3. Co-existing chronic hypertension, diabetes, and epilepsy 4. chronic renal\r<br> or hepatic diseases\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Diagnostic Test: micro RNA 27- FLP1 gene expression;Diagnostic Test: The Expanded Disability Status Scale (EDSS);Diagnostic Test: Electrophysiological assessment:;Diagnostic Test: MRI examination MRI brain:", "primary_outcome": "• To measure the levels of miR-27 expression and its target gene (FSTL1) in progressive MS and relapsing-remitting multiple sclerosis (RRMS) patients.", "secondary_outcome": "To correlate the levels of expression of miR-27 expression and its target gene (FSTL1) relative to the severity of symptoms of MD patients.", "secondary_id": "AOGR", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4290, "title": "E-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity", "summary": null, "published_date": "2024-02-20T00:00:00Z", "discovery_date": "2024-03-13T11:01:28.469252Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06298201", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06298201" }, "categories": [], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13798288", "last_refreshed_on": "2024-03-11", "scientific_title": "Investigating of Effects of e-Based Physical Exercise in Patients With Multiple Sclerosis and Comorbidity", "primary_sponsor": "University of Southern Denmark", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2024-04-27", "target_size": "300", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Participant).", "phase": "N/A", "countries": "Denmark", "contact_firstname": "; ;", "contact_lastname": "Nasrin Asgari, Professor;Nasrin Asgari, Professor;Nasrin Asgari, Professor", "contact_address": null, "contact_email": ";[email protected];[email protected]", "contact_tel": ";+4530700612;+4530700612", "contact_affiliation": "Institute of Regional Health Research, University of Southern Denmark;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> 1. Confirmed MS diagnosis as per the 2017 MS criteria. [3]\r<br>\r<br> 2. Expanded Disability Status Scale (EDSS) assessment score of less than 7.0 at baseline.\r<br>\r<br> 3. Adults aged 18 years or above.\r<br>\r<br> 4. Commitment and mental ability to participate in a 6-month e-based physical exercise\r<br> program, supervised bi-weekly by a physiotherapist.\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> 5. Change in prophylactic DMT within the last 3 months 6. Steroid treatment in the past\r<br> month. 7. Drug or alcohol abuse. 8. Pregnancy. 9. Active systemic infection\r<br>\r<br> -\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: E-Based Physical Exercise Intervention", "primary_outcome": "6-meters' walk test;\"no evidence of disease activity\" (NEDA-3) score", "secondary_outcome": "Cognitive function, evaluated using the Montreal Cognitive Assessment (MoCA),;Fatigue levels, assessed using the short-form Neuro-QOL Fatigue Scale;Neurofilament Light Chain (NfL) determination", "secondary_id": "IMAGINE2024", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4289, "title": "Telerehabilitation Based Motor Imagery and Action Observation Training in Multiple Sclerosis", "summary": null, "published_date": "2024-02-21T00:00:00Z", "discovery_date": "2024-03-13T11:01:28.423236Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06295601", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06295601" }, "categories": [ { "category_id": 18, "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs", "category_name": "Physical therapy and Telerehabilitation", "category_slug": "physical-therapy-and-telerehabilitation", "category_terms": [ "telerehabilitation", "physical therapy", "virtual reality", "gamification", "neurostimulation", "cognitive training", "spasticity", "motor control" ], "article_count": 174 } ], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13809179", "last_refreshed_on": "2024-03-18", "scientific_title": "Effect of Telerehabilitation-Based Motor Imagery and Action Observation Training on Balance and Functional Mobility in Multiple Sclerosis: Randomized Controlled Study", "primary_sponsor": "Inonu University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "65 Years", "inclusion_gender": "All", "date_enrollement": "2024-03-20", "target_size": "10", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Investigator).", "phase": "N/A", "countries": null, "contact_firstname": ";", "contact_lastname": "Burcu talu;Busra CANDIRI", "contact_address": null, "contact_email": ";[email protected]", "contact_tel": ";+9005073780717", "contact_affiliation": "Inonu University;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - Being diagnosed with mulltiple sclerosis according to the McDonald criteria\r<br>\r<br> - Expanded Disability Status Scale<5.5,\r<br>\r<br> - Being between the ages of 18-65,\r<br>\r<br> - Mini mental test score>24,\r<br>\r<br> - Have a phone that can adapt to participating in a video call\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Having another additional neurological disease that may cause balance and coordination\r<br> disorders,\r<br>\r<br> - Receiving physical therapy in the last 6 months,\r<br>\r<br> - Having an attack in the last 3 months\r<br>\r<br> - Refusal to participate in the study.\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: Traditional rehabilitation;Other: Action observation therapy and motor imagery", "primary_outcome": "Berg Balance Scale;Berg Balance Scale;Muscle strength and functional mobility;Muscle strength and functional mobility", "secondary_outcome": "Fatigue Severity Scale;Fatigue Severity Scale;Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire;Multiple Sclerosis International Quality of Life (MusiQoL) questionnaire", "secondary_id": "2024/5591", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4288, "title": "Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis.", "summary": null, "published_date": "2024-02-27T00:00:00Z", "discovery_date": "2024-03-13T11:01:28.335836Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06292312", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06292312" }, "categories": [], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13797835", "last_refreshed_on": "2024-03-11", "scientific_title": "Investigation of the Effectiveness of Craniosacral Therapy in Patients With Multiple Sclerosis: A Randomized Controlled, Single-Blind Study", "primary_sponsor": "Ankara Yildirim Beyazit University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "65 Years", "inclusion_gender": "All", "date_enrollement": "2024-02-27", "target_size": "32", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).", "phase": "N/A", "countries": "Turkey", "contact_firstname": "; ;", "contact_lastname": "Hilal Aslan, MSc;Hilal Aslan, MSc;Hilal Aslan", "contact_address": null, "contact_email": ";[email protected];[email protected]", "contact_tel": ";05372565397;05372565397", "contact_affiliation": "Ankara Yildirim Beyazit University;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - 18 to 65 years old\r<br>\r<br> - Definitive diagnosis of MS by a neurologist\r<br>\r<br> - EDSS score between 1-5.5\r<br>\r<br> - Not receiving active physical therapy services\r<br>\r<br> - Volunteering.\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Having a neurological disease other than MS\r<br>\r<br> - Attacks in the last three months\r<br>\r<br> - Corticosteraoid use\r<br>\r<br> - History of surgery on the spine\r<br>\r<br> - Central and peripheral nervous system disease\r<br>\r<br> - Pregnancy\r<br>\r<br> - Oncological diseases\r<br>\r<br> - Severe comorbid somatic and psychiatric disorders\r<br>\r<br> - Receiving invasive/manipulative treatment.\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: Craniosacral therapy;Other: Conventional physiotherapy", "primary_outcome": "Dynamic posturography;Heart rate variability", "secondary_outcome": "Pain level;Central sensitization;Fatigue;Sleep quality;Life quality", "secondary_id": "19.12.2023/10-483", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4287, "title": "Étude multicentrique, randomisée en double aveugle versus placebo évaluant l’efficacité d’un traitement par Cholécalciférol (Vitamine D3) pour retarder la conversion en SEP après un syndrome cliniq...", "summary": "<p>EudraCT Number: 2013-000910-40<br />Sponsor Protocol Number: PHRC-N/2012/ET-01<br />Sponsor Name: CHU de Nîmes<br />Start Date: 2013-04-12<br />Medical condition: Les patients âgés de 18 à 50 ans ayant présenté depuis moins de 60 jours un SCI typique (NORB, myélite, syndrome du tronc cérébral ou sus-tentoriel) avec présence à l’IRM cérébro-médullaire de plus...<br />Disease: <br />Version: 18.0<br />SOC Term: 100000004852<br />Classification Code: 10028247<br />Term: Multiple sclerosis like syndrome<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href=\"https://www.clinicaltrialsregister.eu/ctr-search/trial/2013-000910-40/FR\">FR</a> (Completed)</p>", "published_date": null, "discovery_date": "2024-03-11T00:08:12.155663Z", "link": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number%3A2013-000910-40", "source": "European Clinical Trials Register", "relevant": null, "identifiers": { "nct": null, "euct": "2013-000910-40", "eudract": "2013-000910-40" }, "categories": [], "export_date": null, "internal_number": null, "last_refreshed_on": null, "scientific_title": null, "primary_sponsor": null, "retrospective_flag": null, "date_registration": null, "source_register": null, "recruitment_status": null, "other_records": null, "inclusion_agemin": null, "inclusion_agemax": null, "inclusion_gender": null, "date_enrollement": null, "target_size": null, "study_type": null, "study_design": null, "phase": null, "countries": null, "contact_firstname": null, "contact_lastname": null, "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": null, "inclusion_criteria": null, "exclusion_criteria": null, "condition": null, "intervention": null, "primary_outcome": null, "secondary_outcome": null, "secondary_id": null, "source_support": null, "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4286, "title": "Multiple Sclerosis treatment with Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A long-term prospective observational study in the Netherlands", "summary": null, "published_date": "2023-02-20T00:00:00Z", "discovery_date": "2024-03-09T20:47:09.442940Z", "link": "https://onderzoekmetmensen.nl/en/trial/53285", "source": "WHO XML import", "relevant": null, "identifiers": { "nl-omon": "NL-OMON53285" }, "categories": [ { "category_id": 12, "category_description": "Autologous Hematopoietic Stem Cell Transplantation (aHSCT) and other stem cell therapies", "category_name": "Stem Cells", "category_slug": "stem-cells", "category_terms": [ "stem cells", "Autologous hematopoietic stem cell", "ahsct" ], "article_count": 221 }, { "category_id": 40, "category_description": "Autologous hematopoietic stem cell transplantation\n\nSearch terms: ahsct,Autologous hematopoietic stem cell transplantation,Bone marrow,Mesenchymal stem cells,Immunoablation", "category_name": "aHSCT", "category_slug": "ahsct", "category_terms": [ "ahsct", "Autologous hematopoietic stem cell transplantation", "Bone marrow", "Immunoablation" ], "article_count": 90 } ], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13758630", "last_refreshed_on": "2024-03-04", "scientific_title": "Multiple Sclerosis treatment with Autologous Hematopoietic Stem Cell Transplantation (MS-ACT): A long-term prospective observational study in the Netherlands\n - MS-ACT", "primary_sponsor": "Vrije Universiteit Medisch Centrum", "retrospective_flag": "Yes", "date_registration": null, "source_register": "NL-OMON", "recruitment_status": "Not Recruiting", "other_records": "No", "inclusion_agemin": "18", "inclusion_agemax": "64", "inclusion_gender": null, "date_enrollement": "2023-09-01", "target_size": "24", "study_type": "Observational invasive", "study_design": "Open (masking not used), Uncontrolled, Treatment", "phase": "4", "countries": "Netherlands", "contact_firstname": null, "contact_lastname": null, "contact_address": "De Boelelaan 1118", "contact_email": null, "contact_tel": null, "contact_affiliation": "Vrije Universiteit Medisch Centrum", "inclusion_criteria": "Inclusion criteria: <p>All patients who undergo aHSCT for the treatment of RRMS in the Netherlands are <br>eligible to participate in this observational study.</p>\r<br>", "exclusion_criteria": "Exclusion criteria: <p>The only exclusion criteria for this observational study is unwillingness to <br>participate or to sign informed consent.</p>\r<br>", "condition": "<br>MS <br>Multiple sclerosis;10003816;10012303", "intervention": "<p></p><br>", "primary_outcome": "<p>Patients will be subjected to frequent visits with clinical, radiological and<br /><br>biomarker follow-up until five years after aHSCT (primary phase and extension<br /><br>phase). During these visits, clinical testing, evaluation by questionnaires,<br /><br>MRI scans and blood sampling will be performed.<br /><br><br /><br>The main study parameters are: 1. no evidence of disease activity (meaning no<br /><br>MS relapses, no disability progression and no MS MRI activity, i.e. NEDA3)</p><br>", "secondary_outcome": "<p>Secundary study parameters are safety and tolerability of aHSCT, biomarkers and<br />\r<br>longitudinal analysis of immune reconstitution.</p>\r<br>", "secondary_id": "NL83783.018.23", "source_support": "Stichting Annie van Coeverden", "ethics_review_status": "Approved", "ethics_review_approval_date": "2023-08-25", "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4285, "title": "The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients:", "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Sponsors</b>: Assiut University\n<br /><b>Not yet recruiting</b>", "published_date": "2024-09-01T00:00:00Z", "discovery_date": "2024-03-09T20:47:05.508190Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06280131", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06280131", "euct": null, "eudract": null }, "categories": [], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13756669", "last_refreshed_on": "2024-03-04", "scientific_title": "The Efficacy of Pulse Therapy in Acute Relapse in Multiple Sclerosis Patients: Clinical and Neurophysiology Study.", "primary_sponsor": "Assiut University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "N/A", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2024-03-01", "target_size": "30", "study_type": "Observational [Patient Registry]", "study_design": null, "phase": null, "countries": null, "contact_firstname": "", "contact_lastname": "Entsar karem, resident", "contact_address": null, "contact_email": "[email protected]", "contact_tel": "0201030698902", "contact_affiliation": null, "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - Any adult patient's clinical history and neuroimaging fulfilling revised McDonald\r<br> diagnostic criteria of Multiple sclerosis in an acute relapsing episode or attack and\r<br> could be providing consent for participation in the study, will be included in the\r<br> study.\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - -Any patient had an infection or febrile condition.\r<br>\r<br> - Any patient had other co-morbid neurological or psychiatric disorders or systemic\r<br> disease or had contraindications for receiving pulse therapy (high steroid dose) or\r<br> showed side effects of steroids or intolerance or seizure.\r<br>\r<br> - Any patient refuses participation in the study.\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": null, "primary_outcome": "to evaluate efficacy of a pulse therapy on clinical outcome", "secondary_outcome": "clinical correlation between clinical scales scores and neurophysiological changes(visual evoked potional;clinical correlation between clinical scales scores and neurophysiological changes( cortical exitability parameters)", "secondary_id": "multiple sclerosis and pulse", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4284, "title": "A French Network for PET Imaging of Neuroinflammation in MS (INFLANET)", "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Radiation: PET-MRI with [18F]-DPA-714\n<br /><b>Sponsors</b>: Assistance Publique - Hôpitaux de Paris\n<br /><b>Not yet recruiting</b>", "published_date": "2024-01-23T00:00:00Z", "discovery_date": "2024-03-09T20:47:05.360242Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06280742", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06280742", "euct": null, "eudract": null }, "categories": [], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13756716", "last_refreshed_on": "2024-03-04", "scientific_title": "A French Network for PET Imaging of Neuroinflammation in MS", "primary_sponsor": "Assistance Publique - Hôpitaux de Paris", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2024-07-01", "target_size": "41", "study_type": "Interventional", "study_design": "Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Other. Masking: None (Open Label).", "phase": "N/A", "countries": "France", "contact_firstname": "", "contact_lastname": "Bruno Stankoff, MD", "contact_address": null, "contact_email": "[email protected]", "contact_tel": "0171970659", "contact_affiliation": null, "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> RRMS patients:\r<br>\r<br> - Age between 18 and 55 years old\r<br>\r<br> - RRMS according to the 2017 Mc Donald criteria\r<br>\r<br> - At least 9 supra-tentorial white matter lesions on T2/FLAIR MRI\r<br>\r<br> - Last treatment with methylprednisolone should have been performed at least 1 month\r<br> before PET examinations\r<br>\r<br> - No current disease modifying therapy\r<br>\r<br> - Indication for a highly active disease modifying treatment: Natalizumab, anti CD20\r<br> antibody, Alemtuzumab, sphingosine-1 phosphate modulator, or cladribine. This will\r<br> consist either as patients with an active form of relapsing MS or patients who have\r<br> experienced two relapses during the previous year\r<br>\r<br> - Affiliation to a social security scheme or beneficiary of such a scheme (except \"Aide\r<br> Médicale d'Etat\")\r<br>\r<br> Healthy Volunteers:\r<br>\r<br> - Age between 18 and 55 years old\r<br>\r<br> - Without any evolutive pathology\r<br>\r<br> - Able to understand the study objectives and procedures\r<br>\r<br> - Affiliation to a social security scheme or beneficiary of such a scheme (except \"Aide\r<br> Me´dicale d'Etat\")\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> For all participants:\r<br>\r<br> - Any reasons, which does not allow to perform MRI, including claustrophobia, the\r<br> implant of a pace-maker or the presence of an intra-ocular foreign body, (a\r<br> contra-indication questionnaire will be filled in beforehand)\r<br>\r<br> - PET for clinical research already done within the last 12 months\r<br>\r<br> - Low Affinity Binding profile (analyse of TSPO polymorphism done at screening visit)\r<br>\r<br> - Pregnancy, breast-feeding, lack of efficient contraception for women of childbearing\r<br> potential\r<br>\r<br> - Current symptoms of severe or uncontrolled renal, hepatic, hematological,\r<br> gastrointestinal, pulmonary or cardiac disease, or any other chronic neurological\r<br> diseases\r<br>\r<br> - Unwillingness to be informed in case of unexpected MRI abnormality (with a significant\r<br> medical anomaly)\r<br>\r<br> - Patient under legal protection\r<br>\r<br> - Participation in another interventional study or being in the exclusion period at the\r<br> end of a previous study\r<br>\r<br> RRMS patients:\r<br>\r<br> - Hypersensitivity to gadoteric acid\r<br>\r<br> - Meglumine or any drug containing gadolinium\r<br>\r<br> - Severe renal insufficiency (creatinine clearance < 60mL/min and GFR <30ml / min /\r<br> 1.73m2).\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Radiation: PET-MRI with [18F]-DPA-714", "primary_outcome": "To quantify the smoldering component of white matter lesions in people with MS, as compared with [18F]-DPA-714 binding in the white matter of HC who underwent a PET a acquisition with the same camera camera than patients in each center.", "secondary_outcome": "To quantify for each patient the regional neuroinflammatory load, measured as [18F]-DPA-714 DVR, in specific regions of interest: total brain, normal appearing white matter, cortex, thalami, deep grey matter.;The MRI signatures of each lesional subtypes, and correlation between MRI metrics and [18F]-DPA-714 DVR in each region of interest.", "secondary_id": "APHP221366", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 4283, "title": "COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS)", "summary": "<b>Conditions</b>: Multiple Sclerosis\n<br /><b>Interventions</b>: Combination Product: Wim Hoff method\n<br /><b>Sponsors</b>: Comenius University\n<br /><b>Active, not recruiting</b>", "published_date": "2024-01-23T00:00:00Z", "discovery_date": "2024-03-09T20:47:05.340315Z", "link": "https://clinicaltrials.gov/ct2/show/NCT06280573", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT06280573", "euct": null, "eudract": null }, "categories": [], "export_date": "2024-03-27T00:00:00Z", "internal_number": "13797305", "last_refreshed_on": "2024-03-11", "scientific_title": "COld Exposure With Controlled BReathing And Meditation in Patients With Multiple Sclerosis (COBRAMS)", "primary_sponsor": "Comenius University", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "55 Years", "inclusion_gender": "All", "date_enrollement": "2022-09-01", "target_size": "50", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Single (Outcomes Assessor).", "phase": "N/A", "countries": "Slovakia", "contact_firstname": null, "contact_lastname": null, "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": null, "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - RRMS diagnosed according to the official 2020 McDonald's criteria,\r<br>\r<br> - age 18-55 years,\r<br>\r<br> - MS duration up to 10 years,\r<br>\r<br> - EDSS 1.0-5.5,\r<br>\r<br> - willingness to participate\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - relapse or corticosteroid treatment within 3 months prior to study enrollment\r<br>\r<br> - severe/unstable comorbidity\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Combination Product: Wim Hoff method", "primary_outcome": "concentration of pro-inflammatory cytokines;concentration of markers of oxidative stress;concentration of NfL;concentration of GFAP;concentration of ecDNA", "secondary_outcome": "Expanded Disability Status Scale;Timed 25-Foot Walk;Nine-Hole Peg Test;Symbol Digit Modalities Test;Fatigue Scale for Motor and Cognitive Functions;General Anxiety Disorder-7;Patient Health Questionnaire-9", "secondary_id": "MS1", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null } ] }{ "count": 4794, "next": "